AIM ImmunoTech
Business Services · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2117 SW Hwy 484, Ocala, Florida, 34473, ...Phone Number
(352) 448-7797Website
www.aimimmuno.comRevenue
<$5 MillionStock Symbol
AIMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About AIM ImmunoTech
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Companys lead product, Ampligen® (rintatolimod), is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.Explore more
AIM ImmunoTech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AIM ImmunoTech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once AIM ImmunoTech has new funding data
Earning: See what the market has to say on AIM ImmunoTech recently announced quarterly report
Check out if AIM ImmunoTech is spiking on competitors!
AIM ImmunoTech, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if AIM ImmunoTech had a recent Job posting/layoffs
Product Launch: Get notified when AIM ImmunoTech launches new products
Congratulate Masked Content for being promoted to Masked Content at AIM ImmunoTech
Check if AIM ImmunoTech has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to AIM ImmunoTech
Compare insights from companies similar to AIM ImmunoTech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
AIM ImmunoTech Tech Stack
A closer look at the technologies used by AIM ImmunoTech
See more technologies
Most Recent Scoops
Project
AIM ImmunoTech has completed the MB-107 clinical trial of Anti-micin to treat soft tissue sarcoma lung metastases, delivering an overall survival of 13.5 months in very late-stage patients receiving an average of seventh-line treatment.
Medical Research, Pharmaceuticals, Clinical Operations
Project
reported complete remission in 50% of second-line AML patients treated with Anti-micin, significantly outperforming any second-line therapy ever approved for AML. The company estimates a large market potential as about half of all cancers are treated with an anthracycline.
Medical Research, Pharmaceuticals, Clinical Operations
Project
AIM ImmunoTech has positioned Anti-micin as a potentially highly disruptive technology in cancer treatment, with a strong patent position and promising safety and efficacy profile. The drug has shown more than double the complete remission rate compared to recently approved targeted therapies in AML, without selecting for mutations, and has potential in dozens of indications beyond AML.
Medical Research, Pharmaceuticals, Clinical Operations
Project
AIM ImmunoTech has announced Anti-micin as its lead drug candidate, which is more potent than existing anthracyclines in most tumor models and generally has fewer and less severe toxic side effects. Anti-micin is part of AIM ImmunoTech's broad portfolio of drug candidates targeting hard-to-treat tumors and viruses.
Research & Development, Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals, Clinical Operations
AIM ImmunoTech News & Media
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpointAIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak Transcript
AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak June 4, 2026 9:00 AM EDTCompany ParticipantsThomas...AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness
Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen’s previously published antiviral researchAIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Treatment, More Than One Month Ahead of Original Target Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Treatment, More Than One Month Ahead of Original Target
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AIM ImmunoTech
Sign Up For FreeTo access detailed company insights
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Companys lead product, Ampligen® (rintatolimod), is an immuno-modulator with broad spectrum activity being developed for globally important cancers,... Read More
